ImClone settles drug patent dispute

The makers of the antibody-based cancer drug Erbitux have settled a patent dispute with Israeli researchers who claimed to have invented the process for making the drug. Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed by the former.) The dispute centered on a long-standing argument between Yale researcher linkurl:Joseph Schlessinger;http://www.